Business
OXB option agreement with GSK
OXB option agreement with GSK.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 8083V Oxford Biomedica PLC 18 December 2013 \n \n\n \nOxford BioMedica Announces Option Agreement with GlaxoSmithKline\n \nOxford, UK - 18 December 2013: Oxford BioMedica plc (\"Oxford BioMedica\" or \"the Company\") (LSE: OXB), the leading gene-based biopharmaceutical company, announces that it has signed an option agreement with GlaxoSmithKline (\"GSK\") which grants GSK an option to a non-exclusive licence under Oxford BioMedica's LentiVector® platform technology patents for the development and commercialisation of up to six product candidates targeting rare orphan diseases. Financial terms were not disclosed. \n \nIn 2006, Oxford BioMedica previously granted GSK a non-exclusive licence to its LentiVector® platform technology patents for research purposes.\n \nJohn Dawson, Chief Executive Officer of Oxford BioMedica, commented: \"With a diverse pipeline of product candidates and a world-class reputation, GSK is a strong licensee of our LentiVector® platform technology patents.\"\n \n- Ends -\n \n\n\n\n\nFor further information, please contact:\n\n\n \n\n\n\n\n \nOxford BioMedica plc:\nJohn Dawson, Chief Executive Officer\nTim Watts, Chief Financial Officer\n\n\n \nTel: +44 (0)1865 783 000\n\n\n\n\n \nMedia Enquiries:\nMary-Jane Elliott/Emma Thompson/Matthew Neal\nConsilium Strategic Communications\n\n\n \n \nTel: +44 (0)20 7920 2354\n\n\n\n\n \nNotes to editors\n \n1. About Oxford BioMedica®\nOxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.\n \n...